Loading clinical trials...
Loading clinical trials...
Multi-center, open-label, non-randomized Phase II study to evaluate the efficacy and safety of OSI-7904L in gastric and GEJ cancers. Those patients who do not derive clinical benefit after two cycles ...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
OSI Pharmaceuticals
NCT06340711 · Esophageal Adenocarcinoma, Gastric Adenocarcinoma, and more
NCT06901531 · Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, and more
NCT05733689 · Gastroesophageal Adenocarcinoma
NCT07282912 · Foregut Adenocarcinoma, Esophageal Adenocarcinoma, and more
NCT05677490 · Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, and more
University of Pennsylvania Cancer Center
Philadelphia, Pennsylvania
MD Anderson Cancer Center
Houston, Texas
University of Utah, Huntsman Cancer Institute
Salt Lake City, Utah
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions